ArticleCancer medicine2026
Impact of Multimodal Oncological Therapy on Survival and Local Control in Unresectable Perihilar Cholangiocarcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the safety and effectiveness of targeted multimodal oncological therapy in patients with unresectable hilar cholangiocarcinoma (HCCA) presenting with obstructive jaundice, particularly those with the nodular-infiltrating morphological type.
methodsA total of 104 patients with Bismuth type III, nodular-infiltrating HCCA were analyzed. Fifty-two patients received percutaneous transhepatic biliary stenting (PTBS) combined with intraluminal
resultsIntraluminal brachytherapy and percutaneous
conclusionsTargeted multimodal oncological therapy may achieve durable local disease control, prolong biliary patency, and improve survival in patients with unresectable nodular-infiltrating HCCA accompanied by obstructive jaundice. Future studies should further consider tumor morphological characteristics and liver function biomarkers when refining treatment strategies and prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.